Ivermectin B1a

• Description:

  Ivermectin B1a, a derivative of Avermectin B1a (HY-15308), is a main component of Ivermectin (HY-15310) [1]. Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19[2].

• UNSPSC:

  12352005

• Hazard Statement:

  H301

• Target:

  Parasite; SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/ivermectin-b1a.html

• Purity:

  99.97

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  C/C ([C@H] ([C@H] (/C=C/C=C1CO[C@] ([H]) ([C@@H] (C (C) =C[C@]2 (C3=O) [H]) O) [C@@]\12O) C) O[C@]4 (C[C@@H] ([C@H] ([C@@H] (O4) C) O[C@@]5 (O[C@H] ([C@@H] ([C@H] (C5) OC) O) C) [H]) OC) [H]) =C\C[C@@]6 (C[C@@] ([H]) (C[C@@]7 (O6) CC[C@@H] ([C@] ([H]) (O7) [C@@H] (C) CC) C) O3) [H]

• Molecular Formula:

  C48H74O14

• Molecular Weight:

  875.09

• Precautions:

  H301

• References & Citations:

  [1]Naftale Kat, et al. Ivermectin Efficacy Against Biomphalaria, Intermediate Host Snail Vectors of Schistosomiasis. J Antibiot (Tokyo) . 2017 May;70 (5) :680-684.|[2]Khan Sharun, et al. Ivermectin, a New Candidate Therapeutic Against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020 May 30;19 (1) :23.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  71827-03-7